Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors

Jean E. Boucher

Robin Sommers

gastroenteropancreatic, neuroendocrine tumors, lutetium Lu 177 dotatate, carcinoid cancer
CJON 2018, 22(5), 565-568. DOI: 10.1188/18.CJON.565-568

Neuroendocrine tumors (NETs), including gastroenteropancreatic NETs, or GEP-NETs, are heterogenous tumors that arise from diffuse neuroendocrine cells and other organs, such as the lung, ovary, and thyroid. Lutetium Lu 177 dotatate (Lutathera®) is a newly approved targeted therapy for patients with advanced GEP-NETs. Patients treated with octreotide long-acting release may be candidates for this second-line therapy. This article discusses lutetium Lu 177 dotatate therapy administration and patient care considerations.


  • Lutetium Lu 177 dotatate therapy has been approved as a treatment for GEP-NETs.
  • Implications for lutetium Lu 177 dotatate as a second-line therapy for patients with GEP-NETs consist of radiation safety precautions and guidelines for the use of long-acting and short-acting somatostatins.
  • Considerations for this therapy include the preadministration of antiemetics and amino acid solution, as well as monitoring for side effects and toxicity.
Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.